#attachment inhibitor

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

ViiV applies for FDA approval of HIV drug fostemsavir

The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.

Given to treatment-experienced people with HIV, the attachment inhibitor BMS-663068 (fostemsavir) demonstrated potentcy in the range of...

Futuristic highlights from the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Bristol-Myers Squibb reported encouraging preliminary results from a short study evaluating its oral version of a new class of...